HOME - Clinical cases - Implantology
 
 
20 November 2019

Osteointegration of titanium implant in patients treated with antiangiogenic targeted chemotherapy

Lara Figini


Recent advances in dental implants have led to an increase in the number of patients treated, with survival rates of more than 95% in a healthy population. More and more frequently dental implant are performed in elderly subjects or in people who have undergone chemotherapy treatments for cancer. Traditional chemotherapy is characterized by a lack of selectivity for tumor cells, that can may lead to drug resistance or result in systemic toxicity. Recently, better targeted treatments, which depend on monoclonal antibodies (mAb) that bind to specific targets on the surface of tumour cells, have been introduced. These differ from traditional treatments as they target cancer cell apoptosis by blocking oncogenic pathways and restricting angiogenesis.
These new chemotherapy drugs, thanks to their selectivity, guarantee fewer side effects, however, require longer treatment times than the traditional ones. But the antiangiogenic targeted chemotherapy can affect the osseointegration of dental implant?

Materials and Methods
In an in vitro animal study, published on British Journal of Oral and Maxillofacial Surgery  February 2019, the authors examined the effect of targeted anti-angiogenetic chemotherapy on the osseointegration of titanium implants. Fourteen white rabbits were allocated randomly into two groups of seven: the placebo control group and the Avastin® group. Animals in the Avastin® group had five doses of bevacizumab intraperitoneally (3 mg/kg/week). The first was given two days before the implant was inserted and the remaining four were given weekly for four weeks. One titanium implant was inserted in the right distal femoral condyle of each rabbit. Osseointegration of the implants was measured using microcomputed tomography (CT) and histomorphometric evaluation.

Results
Both microcomputed tomography and histomorphometric evaluation showed less osseointegration in the Avastin® group than in the controls.

Conclusions
From the data of this study, which must be confirmed with other similar studies and in clinical trials in humans, it can be concluded that the pharmacological inhibition of angiogenesis by bevacizumab can negatively influence the osseointegration of titanium implants on animals.

Clinical implications
The dentist have to  take into consideration that in cases of implantology in patients in therapy or recent undergoned  with chemotherapy-targeted antiangiogenic drugs, the osseointegration can be negatively affected by the intake of bevacizumab specifically.

For additional informations:  Effect of antiangiogenic targeted chemotherapy on the osseointegration of titanium implants in rabbits.

Related articles

Treatments using dental implants to replace missing teeth are effective and predictable. However, with the ever-growing popularity of implant treatments and...


It is estimated that 1 in 2 women and 1 in 5 men over the age of 50 may develop a fracture due to osteoporosis. Osteoporosis is defined as a skeletal disease...


Nowadays patients with fully edentulous maxilla may benefit from different prosthetic rehabilitations. One of them  is the implant-supported overdenture...


The edentulous posterior maxillary region often presents with unique challenging conditions in implant dentistry. Limited bone height secondary to...


Zirconia implants have been brought to the dental market as a viable alternative to titanium implants initially to fulfill a demand from patients for...


Read more

USA     20 February 2020 - 22 February 2020

Midwinter Meeting 2020

Where: McCormick Place West Building, 2301 S. Indiana Ave., ChicagoWhen: on February 20-22, 2020Topic: Restorative dentistry, Oral Cancer Symposium, Implantology, Health and Wellness, The business...


Dentists must regularly determine the best adhesive cementation protocol for glass-ceramic restorations on posterior teeth. A few in vivo follow-up...


Peri-implant mucositis is an inflammation of the mucosa around dental implant. Clinically, it is characterized by mucosal bleeding on peri-implant ...


Intrabony cista in the jaw are the most common benign findings in the oral and maxillofacial area. The best treatment option to manage intrabony cystic lesions...


Clinical management of periodontally compromised teeth with advanced mobility remains an arduous challenge to the dentists. Splints are being used to overcome...


 
 
 
 

Newsletter

 
 
 
 

Most popular

 
 

Events